Robert Hensley, DO
Psychiatry · Tahlequah, OKNPI 1831136407
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $806 of the $1,110 with a category attached, or 72.6%. 9 manufacturers reported payments, led by AbbVie at 27.6% of the total. Reporting peaked in 2022 at $450 and has fallen 95.0% since, to $22 in 2025.
Across 86 payments — averaging $12.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$306
- Teva Pharmaceuticals USA, Inc.$274
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$228
- Sunovion Pharmaceuticals Inc.$147
- Otsuka America Pharmaceutical, Inc.$91
- Novo Nordisk$22
- plus $42 from 3 others
What the payments were for
- Food & beverage$80673%
- Education$30427%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 51 | $306 |
| Teva Pharmaceuticals USA, Inc. | 3 | $274 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $228 |
| Sunovion Pharmaceuticals Inc. | 2 | $147 |
| Otsuka America Pharmaceutical, Inc. | 1 | $91 |
| Novo Nordisk | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LATUDA$125
How this compares
$1,110 in reported general payments places this provider in the 75th percentile of 328 psychiatry providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 18 | $209 |
| Levothyroxine Sodium | 14 | $63 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Tahlequah
- Robert MortonAda$1.9M
- Sarah LandTulsa$287K
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
- Marvin PeytonOklahoma City$60K
- Charles LesterMuskogee$39K
- Josephine DeguzmanOklahoma City$38K
- Jennifer MorrisEdmond$26K
- Julia IrwinNorman$16K
- Bradley McClureTulsa$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.